News
SONN
1.500
-1.96%
-0.030
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform
TipRanks · 1d ago
Sonnet announces ADC platform available for drug discovery partnerships
TipRanks · 1d ago
SONNET BIOTHERAPEUTICS ANNOUNCES THAT ITS PROPRIETARY ANTIBODY DRUG CONJUGATE (ADC) PLATFORM IS AVAILABLE FOR DRUG DISCOVERY PARTNERSHIPS WITH POTENTIAL FOR PRODUCING MULTIPLE PIPELINE DRUG CANDIDATES
Reuters · 1d ago
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Barchart · 2d ago
Weekly Report: what happened at SONN last week (0210-0214)?
Weekly Report · 3d ago
Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments
TipRanks · 5d ago
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 6d ago
Based on the provided financial report articles, I generated the title for the article: "Sonnet BioTherapeutics, Inc. (SONN) Reports Financial Results for the Quarter Ended September 30, 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be related to Sonnet BioTherapeutics' financial results for the quarter ended September 30, 2024.
Press release · 6d ago
Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition
Seeking Alpha · 02/13 13:42
SONNET BIOTHERAPEUTICS APPOINTS STEPHEN MCANDREW, PH.D. AS CHIEF BUSINESS OFFICER
Reuters · 02/13 13:30
Press Release: Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
Dow Jones · 02/13 13:30
Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate
Benzinga · 02/13 13:28
Sonnet BioTherapeutics GAAP EPS of -$1.56
Seeking Alpha · 02/13 13:18
SONNET BIOTHERAPEUTICS HOLDINGS INC: DONALD GRIFFITH, CPA, PROMOTED AS CFO EFFECTIVE FEB 21, 2025
Reuters · 02/13 13:12
SONNET BIOTHERAPEUTICS HOLDINGS INC: JAY CROSS RESIGNS AS CFO, EFFECTIVE FEB 21, 2025
Reuters · 02/13 13:12
SONNET BIOTHERAPEUTICS HOLDINGS INC QTRLY LOSS PER SHARE $1.56
Reuters · 02/13 13:12
Sonnet BioTherapeutics reports Q1 EPS ($1.56) vs ($2.46) last year
TipRanks · 02/13 13:10
Sonnet BioTherapeutics appoints McAndrew as CBO, Griffith as CFO
TipRanks · 02/13 13:10
*Sonnet BioTherapeutics Names Donald Griffith Named New Chief Financial Officer Effective Feb 21
Dow Jones · 02/13 13:07
*Sonnet BioTherapeutics Jay Cross Submitted His Resignation as Chief Fincl Officer, Effective Feb 21 >SONN
Dow Jones · 02/13 13:06
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
More
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).